


To achieve long term capital growth through the active management of a diversified portfolio invested primarily in European stock markets excluding the United Kingdom.
| Name | % Net Assets |
|---|---|
| Roche Holdings | 4.9% |
| Sanofi Aventis | 4.8% |
| BASF Namen-AKT | 4.4% |
| Nestle SA | 4.2% |
| Novartis | 4.0% |
| Bayer Motoren WK | 3.1% |
| Zurich Financial | 2.8% |
| Total | 2.8% |
| BNP Paribas | 2.7% |
| Deutsche Bank | 2.6% |
| Key | % Net Assets |
|---|---|
| 4.9% | |
| 4.8% | |
| 4.4% | |
| 4.2% | |
| 81.7% |
| Date | 02-Mar-2023 |
|---|---|
| NAV | 310.72p |
| Currency | GBP |
| Change | -4.70p |
| % | -1.49% |
| YTD change | 310.72p |
| YTD % | n/a |
| Fund Inception | 01/04/1998 |
|---|---|
| Fund Manager | Quantitative Strategies Team |
| TER | 1.68 (18-Nov-2013) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £250 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research